A detailed history of Candriam S.C.A. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 252,525 shares of REGN stock, worth $198 Million. This represents 1.55% of its overall portfolio holdings.

Number of Shares
252,525
Previous 200,708 25.82%
Holding current value
$198 Million
Previous $211 Million 25.84%
% of portfolio
1.55%
Previous 1.3%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1024.09 - $1201.76 $53.1 Million - $62.3 Million
51,817 Added 25.82%
252,525 $265 Million
Q2 2024

Aug 05, 2024

SELL
$883.2 - $1071.19 $15.1 Million - $18.3 Million
-17,063 Reduced 7.84%
200,708 $211 Million
Q1 2024

May 03, 2024

SELL
$902.69 - $993.35 $21.5 Million - $23.7 Million
-23,847 Reduced 9.87%
217,771 $210 Million
Q4 2023

Feb 14, 2024

SELL
$775.18 - $881.7 $37.7 Million - $42.9 Million
-48,692 Reduced 16.77%
241,618 $212 Million
Q3 2023

Nov 13, 2023

SELL
$692.45 - $844.37 $10.6 Million - $12.9 Million
-15,308 Reduced 5.01%
290,310 $239 Million
Q2 2023

Aug 08, 2023

SELL
$700.03 - $830.35 $30.4 Million - $36 Million
-43,370 Reduced 12.43%
305,618 $220 Million
Q1 2023

May 12, 2023

SELL
$680.49 - $826.97 $23.1 Million - $28.1 Million
-33,980 Reduced 8.87%
348,988 $287 Million
Q4 2022

Feb 13, 2023

SELL
$705.89 - $766.39 $13.8 Million - $15 Million
-19,553 Reduced 4.86%
382,968 $276 Million
Q3 2022

Nov 10, 2022

BUY
$573.97 - $724.32 $17.1 Million - $21.5 Million
29,728 Added 7.97%
402,521 $277 Million
Q2 2022

Aug 03, 2022

BUY
$548.35 - $738.84 $1.92 Million - $2.59 Million
3,503 Added 0.95%
372,793 $220 Million
Q1 2022

May 13, 2022

BUY
$595.12 - $698.43 $2.8 Million - $3.29 Million
4,704 Added 1.29%
369,290 $258 Million
Q4 2021

Feb 10, 2022

SELL
$543.48 - $670.97 $13.1 Million - $16.1 Million
-24,057 Reduced 6.19%
364,586 $230 Million
Q3 2021

Nov 09, 2021

SELL
$574.03 - $680.96 $81.3 Million - $96.5 Million
-141,703 Reduced 26.72%
388,643 $235 Million
Q2 2021

Jul 20, 2021

BUY
$472.8 - $558.54 $59.9 Million - $70.8 Million
126,705 Added 31.39%
530,346 $296 Million
Q1 2021

Apr 29, 2021

BUY
$446.73 - $548.2 $1,786 - $2,192
4 Added 0.0%
403,641 $187 Million
Q4 2020

Jan 22, 2021

BUY
$478.3 - $607.98 $38.6 Million - $49 Million
80,601 Added 24.95%
403,637 $195 Million
Q3 2020

Oct 19, 2020

BUY
$544.75 - $658.21 $51.3 Million - $62 Million
94,135 Added 41.12%
323,036 $181 Million
Q2 2020

Jul 23, 2020

SELL
$493.32 - $643.92 $89.9 Million - $117 Million
-182,315 Reduced 44.34%
228,901 $143 Million
Q1 2020

May 26, 2020

BUY
$336.18 - $494.43 $1,680 - $2,472
5 Added 0.0%
411,216 $151 Million
Q4 2019

Jan 21, 2020

SELL
$274.13 - $376.51 $263,987 - $362,579
-963 Reduced 0.23%
411,211 $154,000
Q3 2019

Oct 21, 2019

BUY
$273.46 - $318.39 $7.23 Million - $8.42 Million
26,433 Added 6.85%
412,174 $114,000
Q2 2019

Aug 01, 2019

BUY
$299.6 - $414.82 $11.5 Million - $16 Million
38,470 Added 11.08%
385,741 $120 Million
Q1 2019

May 02, 2019

SELL
$372.08 - $439.57 $775,042 - $915,624
-2,083 Reduced 0.6%
347,271 $143 Million
Q4 2018

Feb 14, 2019

BUY
$335.82 - $403.04 $997,721 - $1.2 Million
2,971 Added 0.86%
349,354 $130 Million
Q3 2018

Nov 07, 2018

BUY
$351.14 - $408.51 $55.4 Million - $64.5 Million
157,800 Added 83.68%
346,383 $140 Million
Q2 2018

Aug 14, 2018

BUY
$284.6 - $344.99 $16.8 Million - $20.3 Million
58,963 Added 45.49%
188,583 $65.1 Million
Q1 2018

May 09, 2018

BUY
$315.82 - $393.78 $2.69 Million - $3.36 Million
8,528 Added 7.04%
129,620 $44.6 Million
Q4 2017

Feb 07, 2018

SELL
$358.63 - $469.95 $3.55 Million - $4.65 Million
-9,900 Reduced 7.56%
121,092 $45.5 Million
Q3 2017

Nov 03, 2017

BUY
$431.38 - $504.0 $56.5 Million - $66 Million
130,992
130,992 $58.6 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $83.9B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.